Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Top Cited Papers
- 11 February 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 374 (6), 511-522
- https://doi.org/10.1056/nejmoa1505533
Abstract
Original Article from The New England Journal of Medicine — Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraKeywords
This publication has 25 references indexed in Scilit:
- Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpuraHaematologica, 2011
- Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugsBlood, 2011
- Cognitive deficits after recovery from thrombotic thrombocytopenic purpuraTransfusion, 2009
- Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13Journal of Thrombosis and Haemostasis, 2009
- The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989–2007Kidney International, 2009
- Long‐term deficits in health‐related quality of life after recovery from thrombotic thrombocytopenic purpuraTransfusion, 2008
- Myocardial infarction in thrombotic thrombocytopenic purpura: a single‐center experience and literature reviewEuropean Journal of Haematology, 2008
- Current management of thrombotic thrombocytopenic purpuraCurrent Opinion in Hematology, 2008
- Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraBlood, 2008
- Thrombotic thrombocytopenic purpura: Early and late respondersAmerican Journal of Hematology, 1997